Shire Pharmaceuticals
Introducing Shire
- A UK success story
- Global company, UK headquarters
- Employs around 2,400 worldwide, 350 in UK
- Invests considerable revenues in R&D each year
- Expertise in attention deficit and hyperactivity disorder(ADHD), human genetic therapies (HGT), gastrointestinal (GI) andrenal diseases
Founded in 1986, Shire is a British pharmaceutical industry success story. Headquartered in Basingstoke in Hampshire, we currently employ around 2,400 people with 350 jobs being in the UK. Shire is the third largest pharmaceutical company in the UK and operates worldwide with active participation in countries in Europe and North America. Rapidly growing and internationally emerging, our approach is firmly based on the development and marketing of treatments prescribed by specialist doctors.
Shire focuses its business on attention deficit andhyperactivity disorder (ADHD), human genetic therapies (HGT),gastrointestinal (GI) and renal diseases. In the UK, our treatmentsinclude REMINYL� (galantamine hydrobromide) to treat Alzheimer'sdisease, Calcichew D3� and CALCICHEW D3 FORTE� for osteoporosis,REPLAGALTM (agalsidase alfa) for long-term enzyme replacementtherapy in patients with a confirmed diagnosis of Fabry Disease ( a-galactosidase A deficiency), SOLARAZE� (dicolfenac sodium 3%) foractinic keratosis (pre-cancerous skin lesions) and XAGRID�(anagrelide hydrochloride) for the reduction of elevated plateletcounts in at-risk essential thrombocythaemia patients. In addition,in the United States we market ADDERALL XR� (mixed amphetaminesalts), DAYTRANA� (methylphenidate transdermal system) forattention deficit hyperactivity disorder and ELAPRASETM(idursulfase) for the long-term treatment of patients with Huntersyndrome (Mucopolysaccharidosis II).
The world's most prescribed HIV treatment, 3TC, a registeredtrademark of GSK, was discovered by Shire Biochem and is licensedto GSK.
In addition to developing and marketing drug therapies, Shire also takes an active interest in policy development both in the broader NHS and in the disease areas where we have a particular specialism. As well as inputting directly into the various NHS reform processes, we are also involved in various initiatives in the UK to help to improve the standard of care received by patients at local level especially in osteoporosis, old age psychiatry and skin disease. This includes working with the Modernisation Agency and NHS collaboratives to help to deliver, as cheaply and effectively as possible, the target that all ambulatory patients residing in residential homes should be prescribed calcium and vitamin D.
To view our 2005 online annual review and summary financialstatement please click here.
Latest Press Releases
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
- Shire and TAP Agree to Co-promote LIALDA™ (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
- Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
- RENOVO ANNNOUNCES JUVISTA® PHASE 2 TRIAL RESULTS IN SCAR REVISION AND BREAST AUGMENTATION SURGERY
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
